Evidence map›Paper›PMID 32960359›Full record

ArticleJournal of cancer research and clinical oncology2021

Analysis of genomic pathogenesis according to the revised Bethesda guidelines and additional criteria.

Jin Cheon Kim, Jong Hwan Kim, Ye Jin Ha, Chan Wook Kim, Ka Hee Tak, Yong Sik Yoon, Yi Hong Kwon, Seon Ae Roh, Dong-Hyung Cho, Seon-Kyu Kim and 2 more

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Pan-cancer analysis and oncogenic implications ofJournal of cell communication and signaling · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Genomic landscape of colorectal carcinogenesis.Journal of cancer research and clinical oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jin Cheon Kim *Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. jckim@amc.seoul.kr.ORCID http://orcid.org/0000-0003-4823-8619
Jong Hwan Kim *Institute of Innovative Cancer Research, University of Ulsan College of Medicine and Asan Medical Center, Seoul, 05505, Korea.
Ye Jin HaDepartment of Surgery, University of Ulsan College of Medicine and Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Chan Wook KimDepartment of Surgery, University of Ulsan College of Medicine and Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Ka Hee TakDepartment of Surgery, University of Ulsan College of Medicine and Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Yong Sik YoonDepartment of Surgery, University of Ulsan College of Medicine and Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Yi Hong KwonInstitute of Innovative Cancer Research, University of Ulsan College of Medicine and Asan Medical Center, Seoul, 05505, Korea.
Seon Ae RohInstitute of Innovative Cancer Research, University of Ulsan College of Medicine and Asan Medical Center, Seoul, 05505, Korea.
Dong-Hyung ChoSchool of Life Science, Kyungpook National University, Daegu, 41566, Korea.
Seon-Kyu KimInstitute of Innovative Cancer Research, University of Ulsan College of Medicine and Asan Medical Center, Seoul, 05505, Korea.
Seon-Young KimPersonalized Genomic Medicine Research Center, Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology, 52 Eoeun-dong Yuseong-gu, Daejeon, 34141, Korea. kimsy@kribb.re.kr.
Yong Sung KimInstitute of Innovative Cancer Research, University of Ulsan College of Medicine and Asan Medical Center, Seoul, 05505, Korea.

Funding

the National Research Foundation of Korea (NRF) 2016R1E1A1A02919844the National Research Foundation of Korea (NRF) 2017R1A2B1009062the National Research Foundation of Korea (NRF) 2020R1C11009345
6 · The paper itself

Abstract

purposeAs few genotype-phenotype correlations are available for nonsyndromic hereditary colorectal cancer (CRC), we implemented genomic analysis on the basis of the revised Bethesda guideline (RBG) and extended (12 items) to verify possible subtypes.

methodsPatients with sporadic CRC (n = 249) were enrolled, stratified according to the revised Bethesda guidelines (RBG+ and RBG- groups) plus additional criteria. Exome/transcriptome analyses (n = 98) and cell-based functional assays were conducted.

resultsWe detected 469 somatic and 830 germline gene mutations differing significantly between the positive and negative groups, associated with 12 RBG items/additional criteria. Twenty-one genes had significantly higher mutation rates in left, relative to right, colon cancer, while USP40, HCFC1, and HSPG2 mutation rates were higher in rectal than colon cancer. FAT4 mutation rates were lower in early-onset CRC, in contrast to increased rates in microsatellite instability (MSI)-positive tumors, potentially defining an early-onset microsatellite-stable subtype. The mutation rates of COL6A5 and MGAM2 were significantly and SETD5 was assumably, associated CRC pedigree with concurrent gastric cancer (GC). The predicted deleterious/damaging germline variants, SH2D4A rs35647122, was associated with synchronous/metachronous CRC with related tumors, while NUP160 rs381660 and KRTAP27-1 rs2244485 were potentially associated with a GC pedigree and less strictly defined hereditary CRC, respectively. SH2D4A and NUP160 acted as oncogenic facilitators.

conclusionOur limited genomic analysis for RBG and additional items suggested that specific somatic alterations in the respective items may enlighten relevant pathogenesis along with the knowledge of germline mutations. Further validation is needed to indicate appropriate surveillance in suspected individuals.

Indexed as

Microsatellite InstabilityMutationBiomarkers, TumorColorectal NeoplasmsGenetic TestingHigh-Throughput Nucleotide SequencingHumansPrognosisBiomarkers, TumorHereditary colorectal cancerNGSNonsyndromicRevised Bethesda guidelineSNP

Identifiers

PMID32960359
PMCPMC11802017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.